Femasys (FEMY) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Femasys (FEMY) over the past year, gaining 84.8% versus a loss of 82.9%. Over five years, HBIO leads with a -88.1% price change compared with -98.5% for FEMY. Harvard Bioscience is the larger company by market cap ($37.1 million vs $17.4 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | HBIO |
|---|---|---|
| Share price | $2.08 | $8.16 |
| Market cap | $17.38M | $37.12M |
| 1-day change | +1.46% | +0.30% |
| YTD return | -82.25% | +21.34% |
| 1-year return | -82.87% | +84.77% |
| 5-year return | -98.54% | -88.11% |
| Forward P/E | — | 12.64 |
| EPS (TTM) | $-3.28 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.20 | $9.40 |
| 52-week low | $1.94 | $3.80 |
| Distance from 52-week high | -90.65% | -13.24% |
| Analyst consensus | none | none |
| Avg. price target upside | +590.60% | -8.03% |
| Average volume | 722.09K | 17.98K |
| Shares outstanding | 8.38M | 4.55M |
| Employees | 51 | 316 |
| Sector | Health Care | Industrials |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Harvard Bioscience is about 2.1 times larger than Femasys by market value ($37.12M vs $17.38M).
- HBIO has outperformed FEMY by 167.6 percentage points over the past year.
- The two companies sit in different sectors: Femasys in Health Care and Harvard Bioscience in Industrials.
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
FEMY vs HBIO FAQ
Which is bigger, Femasys or Harvard Bioscience?
Harvard Bioscience (HBIO) is larger, with a market capitalization of $37.12M compared with $17.38M for Femasys (FEMY).
Which stock has performed better over the past year, FEMY or HBIO?
HBIO returned +84.77% over the past 12 months, compared with -82.87% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Femasys and Harvard Bioscience in the same industry?
No. Femasys is in the Health Care sector, while Harvard Bioscience is in Industrials.